Heading1

Men with nmCRPC who added NUBEQA to hormone therapy* lived more than twice as long without prostate cancer spreading to other parts of their body compared with men on hormone therapy alone (median 3.4 yrs vs 1.5 yrs).

Graph of 3.4 years lived without cancer spreading on Nubeqa and hormone therapy vs 1.5 years without cancer spreading on hormone therapy alone
Graphic with text Men lived 2X longer without cancer spreading vs hormone therapy alone

*Hormone therapy includes drug treatments or surgery to lower testosterone.Median is the middle value in a set of numbers, not the average.nmCRPC=non-metastatic castration-resistant prostate cancer, a type of prostate cancer that has not spread to other parts of the body and no longer responds to hormone therapy.

How NUBEQA was studied in nmCRPC

NUBEQA + hormone therapy was compared with hormone therapy alone in 1509 men with nmCRPC

Graphic of for 955 men who received Nubeqa (darolutamide) in the trial with hormone therapy
Graphic of 654 men who did not receive Nubeqa (darolutamide) in the clinical trial
Heading2

Men with nmCRPC who added NUBEQA to hormone therapy had a 31% lower
risk of dying than men on hormone therapy alone.

Graphic of a down arrow with text 31% lower risk of death with Nubeqa

Another way to look at the results:

In the study for nmCRPC, more men who added NUBEQA to hormone therapy
were still alive at 3 years compared with men on hormone therapy alone.

Graphic of 10 blue men with 8.3 highlighted with text of 83% of men were still alive with Nubeqa and hormone therapy
Graphic of 10 blue men with 7.7 highlighted with text of 77% of men were still alive with Nubeqa and hormone therapy alone
Heading3

NUBEQA gave men more time with less pain

It took 15 extra months for pain to get worse in men with nmCRPC who added
NUBEQA to hormone therapy compared with men on hormone therapy alone
(median duration 40.3 months vs 25.4 months).

Graph of 40.3 months with less pain on Nubeqa and hormone therapy vs 25.4 months with less pain on hormone therapy alone Graph of 40.3 months with less pain on Nubeqa and hormone therapy vs 25.4 months with less pain on hormone therapy alone

Median is the middle value in a set of numbers, not the average.

NUBEQA delayed the need for chemotherapy

In the study for nmCRPC, more men who added NUBEQA to hormone therapy did
not receive chemotherapy at 3 years compared with men on hormone therapy alone.

Graph of 10 blue men with 8.3 highlighted with text of 83% did not need chemotherapy with Nubeqa and hormone therapy
Graph of 10 grey men with 7.5 highlighted with text of 75% did not need chemotherapy with hormone therapy alone

TALK TO YOUR HEALTHCARE PROVIDER TO SEE IF NUBEQA MAY BE RIGHT FOR YOU

A man in a navy shirt with a motorcycle in the forefront